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Stroke is a potential complication of treating patients with aortic stenosis via surgical aortic valve replacement
(AVR), transcatheter aortic valve replacement (TAVR), and balloon aortic valvuloplasty. Because there are limited
and heterogeneous data on the incidence, risk factors, and outcomes of stroke among patients being treated for
aortic stenosis, we performed a comprehensive review of the literature. The risk of stroke after AVR in the gen-
eral population is approximately 1.5%, and the risk is increased (to approximately 2% to 4%) in older and higher-
risk patients. Strokes were reported in 1.5% to 6% of patients treated with TAVR, and in the only randomized
trial of AVR versus TAVR, there was an increased risk of 30-day strokes (minor and major strokes and transient
ischemic attacks) with TAVR (5.5% vs. 2.4%, p  0.04). (J Am Coll Cardiol 2011;58:2143–50) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.024S
bStroke is a potential major complication of aortic valve
replacement (AVR), transcatheter aortic valve replacement
(TAVR), and balloon aortic valvuloplasty (BAV). Although its
occurrence is rare, stroke significantly affects survival and
quality of life. Based on recent randomized data from the
PARTNER (Placement of Aortic Transcatheter Valves) trial,
TAVR has recently emerged as the preferred therapy for
inoperable patients and as an alternative to surgical AVR in
high-risk patients (1,2). Importantly, increased neurologic
events associated with TAVR have raised concerns (2). We
reviewed the available literature to better understand the
frequency, predictors, and clinical impact of post-procedure
stroke during different aortic valve therapies for aortic stenosis.
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accepted August 2, 2011.Potential Sources of Embolization
Although strokes during either AVR or TAVR are un-
doubtedly multifactorial, the dominant etiology is likely
intraprocedure embolic events. A transcranial Doppler study
during TAVR demonstrated that the majority of procedural
embolic events occurred during balloon valvuloplasty, ma-
nipulation of catheters across the aortic valve, and valve
implantation (3). During AVR, evidence of emboli from
transcranial Doppler imaging was mainly seen during inser-
tion of an aortic cannula at the start of cardiopulmonary
bypass and after declamping the aorta with the heart beating
while empty (4). Late embolic events post-AVR are pre-
sumably caused by debris from the prosthesis (5).
Stroke in Surgical AVR Patients
The overall rate of stroke for isolated AVR in the global
U.S. population is approximately 1.5% based on the Society
of Thoracic Surgeons (STS) database (6,7). The incidence
of stroke for blacks and whites among 34,510 isolated AVR
procedures performed between 1999 and 2002 was 1.5% (26
of 1,762) and 1.7% (550 of 32,748), respectively (6).
imilarly, O’Brien et al. (7) reviewed 67,292 isolated AVRs
etween 2002 and 2006 in the United States and found a
umulative stroke rate of 1.5%.
e
p
n
o
s
e
p
h
s
(
(
i
o
S
3
O
a
t
v
l
t
s
(
a
2
m
A
(
(
O
p
e
M
o
p
w
o
w
a
V
r
2144 Daneault et al. JACC Vol. 58, No. 21, 2011
Stroke Associated With Aortic Stenosis Treatment November 15, 2011:2143–50Several studies have specifically
examined the outcomes of high-
risk elderly patients undergoing
heart surgery (Table 1). In these
multiple small series, the stroke
frequency in high-risk patients
undergoing AVR was increased
(to as high as 4%), and important
predictors were age (older than
80 years) and mean logistic Euro-
SCORE (European System for
Cardiac Operative Risk Evalua-
tion) (8–16). In the largest single-
center study including 249 octo-
genarians (STS score: 10.5%) who
had a mini AVR (hemi-upper
sternotomy), there was a 3%
perioperative mortality, but 4%
of patients had strokes (15). A
multicenter group retrospectively
evaluated the outcomes of 159
high-risk AVR patients (mean
STS score of 16.3% and fulfilling
other criteria of the PARTNER AVR vs. TAVR trial),
treated in 2002 through 2007 in 4 U.S. hospitals (17). The
arly mortality rate was 16.4%; 4.4% of patients had
ermanent strokes and an additional 2.5% had transient
eurologic events.
The addition of coronary artery bypass graft (CABG)
r other procedures to AVR in octogenarians appears to
ignificantly increase the risk of neurologic events. Sundt
t al. (18) reported a 4% risk of stroke among 133
atients with AVR; 67% had an AVR-CABG and 11.3%
ad concomitant mitral valve replacement or repair. A
ingle-center experience with AVR in octogenarians
28% with concomitant CABG) reported strokes in 5.8%
6 of 104) (19), and Alexander et al. (20) observed a 4.9%
ncidence (17 of 345) of stroke after AVR-CABG among
ctogenarians.
Abbreviations
and Acronyms
AVR  surgical aortic valve
replacement
BAV  balloon aortic
valvuloplasty
CABG  coronary artery
bypass graft
CI  confidence interval
DW-MRI  diffusion-
weighted magnetic
resonance imaging
EF  ejection fraction
HR  hazard ratio
OR  odds ratio
STS  Society of Thoracic
Surgeons
TA  transapical
TAVR  transcatheter
aortic valve replacement
TF  transfemoral
Stroke After Isolated AVR in Moderate- and High-Risk PatientsTable 1 Stroke After Isolated AVR in Moderate- and High-Risk
First Author (Ref. #) Type of Study
High-risk feature: 80 yrs of age
Thourani et al. (8) Retrospective, single-center
Leontyev et al. (9) Retrospective, single-center
Culliford et al. (10) Retrospective, single-center
Akins et al. (11) Retrospective, single-center
Kolh et al. (12) Retrospective, single-center
Ennker et al. (13) Retrospective, single-center
Ferrari et al. (14) Retrospective, single-center
Elbardissi et al. (15)† Retrospective, single-center
High-risk feature: STS 10%
Thourani et al. (17) Retrospective, multicenter*2 of 100 cases (70 isolated aortic valve regurgitation [AVR] and 30 AVR/coronary artery bypass graft);
EuroSCORE  European System for Cardiac Operative Risk Evaluation; STA  Society of Thoracic SurgStroke and TAVR
Observational data with Edwards SAPIEN: transfemoral
approach. Five registries and 1 randomized trial reported
stroke outcomes with the Edwards SAPIEN transcatheter
heart valve (Edwards Lifesciences, Irvine, California) using
a transfemoral (TF) approach (1,2,21–25). Reported strokes
in these 5 registries ranged from 2.4% to 6% (Table 2)
(21–25). In the SAPIEN Aortic Bioprosthesis European
Outcome registry, the largest registry of Edward SAPIEN
TF cases, strokes were observed in 2.5% of patients (23).
imilarly, the Multicenter Canadian experience reported a
0-day stroke rate of 3.0% for TF cases (22).
bservational data with Edwards SAPIEN: transapical
pproach. Two feasibility trials evaluating only the
ransapical (TA) approach using the Edwards SAPIEN
alve reported strokes in 2% and 5% of patients (26,27). The
arger TRAVERSE trial (the initial multicenter feasibility
rial for TA-AVI) included 168 patients, and the rates of
troke at 30 days and 1 year were 2% and 5%, respectively
26). In the 5 registries discussed previously (21–25) that
lso included TA patients, strokes were noted in as many as
.8% of the TA cases (Table 2). In a small retrospective
atched study comparing the outcomes of TAVR and
VR with a TA approach via a partial upper sternotomy
28), there were no strokes in the TAVR patients and 1
3%) in the AVR group.
bservational data with CoreValve. Four registries re-
orted stroke-related clinical outcomes with the self-
xpanding CoreValve system (Medtronic, Minneapolis,
innesota) (Table 2) (21,29–31). In 1 registry looking at
utcomes with the first 3 generations of devices, the overall
rocedure rate of stroke was 4.4% (6 of 136), but was lower
ith the third-generation device (2.9% [3 of 102]) (29). In the
ther registries, 30-day strokes ranged between 1.9% and 4.5%
ith the TF approach with the 18-F device (21,30,31). There
re limited data on the subclavian approach with the Core-
alve (Medtronic) and the largest cohort of subclavian patients
eported a 1.9% in-hospital stroke rate (30).
nts
STS Mean EuroSCORE
In-Hospital
Death Stroke
— — 5.7% 3.4%
— 16.2% 10.6% 1.4%
— — 5.7% 0%
— — 8.0% 1.0%
— — 8.5% 2.0%*
— — 4.8% 0%
— 12.6% 6.0% 2.0%
10.5% 11.0% 3% 4.0%
16.3% — 16.4% 4.4%Patie
n
88
282
35
105
70
62
124
249
159†Mini AVR.
eons; STS  Society of Thoracic Surgeons.
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November 15, 2011:2143–50 Stroke Associated With Aortic Stenosis TreatmentIn a multidevice series of 697 patients treated with
TAVR, the overall rate of in-hospital stroke was 2.8% (32);
a TF approach was used in most patients (92.4%) and most
were treated with the CoreValve (84.4%).
Difficulties in Interpreting Stroke Data
Across AVR and TAVR Studies
In much of the current AVR literature, stroke is poorly
defined and usually is not independently adjudicated. The
majority of studies reported in-hospital mortality, and
stroke is included among an overall assessment of in-
hospital morbidity. Definitions (when they are available)
have varied from crude determinations of a new neurologic
deficit to more sensitive discriminations of stroke severity
(33). In contrast, most TAVR studies have 30-day and
often 1-year follow-up and attempt to apply a more consis-
tent definition of stroke, but with varying ascertainment and
adjudication. It is likely that without prospective assessment
and follow-up, dedicated neurologic evaluations to adjudi-
cate events, and confirmatory neuroimaging studies, strokes
were systematically underreported in these registries. This
limitation renders cross-study comparisons of published
observational data problematic. In a recent effort to better
define endpoints after TAVR, the Valve Academic Re-
search Consortium proposed standardized endpoint defini-
Stroke After TAVR According to Access Site and Device Type: MajTable 2 Stroke After TAVR According to Access Site and Devic
First Author (Ref. #) Type of Study n STS
Edwards Sapien: TF
Lefevre et al. (25) Registry 61 11.3%
Eltchaninoff et al. (21) Registry 95 17.4%
Himbert et al. (24) Registry 51 15.0%
Rodes-Cabau et al. (22) Registry 113 9.0%
Thomas et al. (23) Registry 463 —
Leon et al. (1) RCT 179 11.2%
Edwards Sapien: TA
Walther et al. (26) Feasibility study 168 —
Svensson et al. (27) Feasibility study 40 13.4%
Lefevre et al. (25) Registry 69 11.3%
Eltchaninoff et al. (21) Registry 71 18.4%
Himbert et al. (24) Registry 24 18.0%
Rodes-Cabau et al. (22) Registry 177 10.5%
Thomas et al. (23) Registry 575 —
Medtronic CoreValve: TF
Grube et al. (29) Registry 136 —
Piazza et al. (31) Registry 646 —
Eltchaninoff et al. (21) Registry 66 21.3%
Petronio et al. (30) Registry 460 —
Medtronic CoreValve: SC
Eltchaninoff et al. (21) Registry 12 21.0%
Petronio et al. (30) Registry 54 —
Zahn et al. (32) Registry 697 —
*In-hospital outcome; †All stroke (major and minor) or transient ischemic attack; ‡1-year follow-u
SC  subclavian; TA  transapical; TAVR  transcatheter aortic valve replacement; TF  transtions for a number of endpoints including stroke (Table 3) athat should help to standardize and make future TAVR and
AVR study methodologies more rigorous (33).
Another barrier to the interpretation of available data
relates to discrepancies in the treated population across
studies as well as the type of surgery performed (e.g., AVR,
AVR-CABG). Also, the presence or absence of important
comorbidities and other high-risk features is variably re-
ported, such as atrial fibrillation. Only a minority of papers
have included some form of presurgical risk assessment
(e.g., STS or EuroSCORE) (9,34).
Randomized Trials of TAVR
In the inoperable cohort of the randomized PARTNER trial
(1), which randomized TF-TAVR versus standard therapy
ith prospective ascertainment of stroke outcomes and careful
vent monitoring, the rate of all strokes and transient ischemic
ttacks at 30 days was 6.7% for the 179 patients after TAVR
nd 1.7% after standard therapy (p  0.03). At 1-year
follow-up, strokes and transient ischemic attacks were 10.6%
and 4.5% after TAVR and standard therapy, respectively (p
.04). The rate of major stroke (modified Rankin Scale score of
2) was 5% at 30 days and 7.8% at 1 year.
In the PARTNER trial comparing TAVR and surgical AVR
n high-risk patients (2) (n  348 TAVR [TF and TA]; 351
VR), strokes and transient ischemic attacks were more frequent
blished Datape: Major Published Data
ORE
Follow-Up,
Months
Death Stroke
30-day 1-yr 30-day 1-yr
% 12 8.2% 21.3% 3.3% 7.0%
% 1 8.4% — 4.2% —
% 12 8.0%* 19.0% 6.0%* —
24 9.5% 25.0% 3.0% —
% 1 6.3% 18.9% 2.4% —
% 12 5.0% 30.7% 6.7%† 10.6%†
% 12 15.0% 37.0% 2.0% 5.0%
% 6 17.5% — 5.0% —
% 12 18.8% 50.7% 1.5% 10.3%
% 1 16.9% — 2.8% —
% 12 16.0%* 26.0% 0%* —
1 11.3% 22.0% 1.7% —
% 1 10.3% 27.9%‡ 2.6% —
% 12 12.5% 29.8% 4.4% 7.1%‡
% 1 8.0% — 1.9% —
% 1 15.1% — 4.5% —
% 6 6.1% 11.4% 1.7% —
% 1 8.3% — 0% —
% 6 0% 6.7% 1.9% —
% 1 12.4% — 2.8%* —
patients.
l; other abbreviations as in Table 1.or Pue Ty
EuroSC
25.7
25.6
25.0
—
14.5
26.4
27.0
35.5
33.8
26.8
28.0
—
16.3
23.1
23.1
24.7
19.4
24.6
25.3
20.5fter TAVR than AVR at both 30 days and 1 year (30 days: 5.5%
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Stroke Associated With Aortic Stenosis Treatment November 15, 2011:2143–50TAVR vs. 2.4% AVR, p  0.04; and 1 year: 8.3% TAVR vs.
.3% AVR, p  0.04). Major strokes were 3.8% after TAVR
ersus 2.1% with AVR (p  0.20) at 30 days and 5.1% versus
2.4% (p 0.07) at 1 year, whereas all-cause mortality was similar
for both groups at 30 days and 1 year. The combined endpoint of
all strokes (or major strokes) and mortality was similar for TAVR
and AVR at early and late time points.
Stroke and BAV
With the emergence of TAVR, there has been a resur-
gence in BAV. In recent series of BAV, the observed
stroke rates were found to be approximately 1% to 2%
(35–39). The largest single-center cohort of patients (301
BAV in 262 patients) reported a stroke rate of 2% (35).
In the PARTNER trial, 150 BAVs were performed in
the medical therapy arm with only 2 strokes occurring
(1.3%) (39).
Neuroimaging After AVR and TAVR
Three small studies used diffusion-weighted magnetic res-
onance imaging (DW-MRI) before and after AVR, and
new imaging abnormalities (5 to 7 days after AVR) were
observed in 38% (4 of 37), 40% (6 of 15), and 47% (14 of
30) of patients (40–42). Clinical strokes were less frequent
VARC Definition of StrokeTable 3 VARC Definition of Stroke
Stroke diagnostic criteria
1. Rapid onset of a focal or global neurological deficit with at least 1 of the
following: change in level of consciousness, hemiplegia, hemiparesis,
numbness or sensory loss affecting one side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or
symptoms consistent with stroke
2. Duration of a focal or global neurological deficit 24 h; OR 24 h, if
therapeutic intervention(s) were performed (e.g., thrombolytic therapy or
intracranial angioplasty); OR available neuroimaging documents a new
hemorrhage or infarct; OR the neurological deficit results in death
3. No other readily identifiable nonstroke cause for the clinical presentation
(e.g., brain tumor, trauma, infection, hypoglycemia, peripheral lesion,
pharmacological influences)*
4. Confirmation of the diagnosis by at least 1 of the following:
Neurology or neurosurgical specialist
Neuroimaging procedure (MR or CT scan or cerebral angiography)
Lumbar puncture (i.e., spinal fluid analysis diagnostic of intracranial
hemorrhage)
Stroke definitions
Transient ischemic attack:
New focal neurological deficit with rapid symptom resolution
(usually 1–2 h), always within 24 h
Neuroimaging without tissue injury
Stroke: (diagnosis as above, preferably with positive neuroimaging study)
Minor—modified Rankin score 2 at 30 and 90 days†
Major—modified Rankin score 2 at 30 and 90 days
*Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal
evidence based upon neuroimaging studies. †Modified Rankin score assessments should be made
by qualified individuals according to a certification process. If there is discordance between the 30-
and 90-day modified Rankin scores, a final determination of major versus minor stroke will be
adjudicated by the neurology members of the clinical events committee.
CT  computed tomography; MR  magnetic resonance; VARC  Valve Academic Research
onsortium.(8%, 13%, and 0%, respectively), although 13% of patients had owhat was described as a “transient psychotic syndrome” in 1
study (42). Although several studies demonstrated a transient
deterioration in neurocognitive function early after valve sur-
gery, there was complete recovery within 4 months (42).
Similar DW-MRI studies after TAVR revealed an even
greater number of new ischemic lesions (in 68% to 84% of
patients), and in the vast majority of cases, these perfusion
abnormalities have also not resulted in clinical strokes
(43–46). Rodes-Cabau et al. (44) evaluated 29 TA and 31
TF patients treated by TAVR with the Edwards SAPIEN
valve, and the proportion of patients with new DW-MRI
deficits was similar for TA and TF patients (71% vs. 66%,
respectively). Only 2 patients (3.3%) (1 in each group) had
a stroke within 24 h of the procedure, and there were no
significant differences in neurocognitive function in those
with and without perfusion changes.
Neuroimaging outcomes after TAVR have been com-
pared with an historical cohort of AVR patients (46). New
ischemic lesions on DW-MRI were significantly increased
with TAVR (86% [19 of 22] for the Edwards SAPIEN vs.
80% [8 of 10] for the CoreValve and 48% [10 of 21] for
AVR). However, the 32 TAVR patients were older and had
higher logistic EuroSCOREs and more comorbidities than
the surgical patients. Moreover, although the number of
lesions increased after TAVR, the lesion size was 3 to 4
times larger after surgical AVR. Despite the high propor-
tion of abnormal neuroimaging studies, no clinical strokes
were observed after TAVR, whereas 1 (4.7%) occurred in
the surgical group.
Risk Factors for Post-Procedure Stroke
Limited information is available regarding risk factors for
postoperative stroke after AVR and TAVR. Low ejection
fraction (EF) has been identified as an independent risk
factor for neurologic events (47,48). Stroke was significantly
more frequent in AVR (including aortic regurgitation) in
patients with an EF40% compared with those with an EF
40% (5.5% vs. 2.0%, p  0.005). A single-center retro-
pective analysis also identified low EF as an independent
redictor of stroke; the stroke rate was 3% for isolated AVR
nd an EF 30% compared with 1% for patients with an
F 30% (48).
Extensive calcification of the ascending aorta is believed
o increase the risk of neurologic complications after AVR
nd is frequently a high-risk feature that dissuades surgeons
rom performing AVR. Girardi et al. (49) reported strokes
n 4% of 25 patients with a “porcelain aorta” undergoing
ortic valve surgery using a no-clamp technique. Similarly,
illinov et al. (50) reported the outcome of 62 patients with
xtensive calcification of the ascending aorta undergoing
VR, and the risk of permanent stroke was 10%, but
iffered based on the different management strategies of the
scending aorta.
Age remains a risk factor for stroke; in 1 series, it was thenly multivariable predictor of neurologic events (51).
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November 15, 2011:2143–50 Stroke Associated With Aortic Stenosis TreatmentHowever, a more robust multivariable analysis in patients
undergoing valve surgery (not only AVR) revealed 4 base-
line characteristics and 2 procedural events that were asso-
ciated with early post-procedure stroke: female sex (odds
ratio [OR]: 2.6; 95% confidence interval [CI]: 1.5 to 4.8),
EF30% (OR: 2.3; 95% CI: 1.2 to 4.5), diabetes (OR: 2.2;
95% CI: 1.2 to 4.2), age older than 70 years (OR: 2.0; 95%
CI: 1.1 to 3.6), bypass procedure time 120 min (OR: 3.7;
95% CI: 1.1 to 14.4), and calcification of the ascending
aorta (OR: 2.6; 95% CI: 1.3 to 5.8) (52). Of note, atrial
fibrillation was not included in the model. Among
patients with an EF 40% in another study, additional
multivariate predictors of stroke were peripheral vascular
disease, a history of stroke or cerebrovascular disease, and
diabetes (47,53). Finally, walking 300 m during a
6-min walk test has been demonstrated to be predictor of
stroke after AVR (54).
Late embolic stroke after surgical AVR is also a concern.
Follow-up of 2,317 patients with AVR revealed an annual
rate of stroke of 1.3% for bioprostheses and 1.4% for
mechanical valves (55). In comparison, the annual rate of
major bleeding was 1.0% with anticoagulation and 0.4%
without. Multivariate predictors of late stroke have included
female sex (hazard ratio [HR]: 1.76; 95% CI: 1.26 to 2.48),
age older than 75 years (HR: 1.88; 95% CI: 1.11 to 2.78),
atrial fibrillation (HR: 2.21; 95% CI: 1.13 to 4.15), a history
of or current smoking (HR: 2.59; 95% CI: 1.73 to 3.71 and
HR: 2.96; 95% CI: 1.97 to 6.12, respectively), number of
grafts performed (HR: 1.24; 95% CI: 1.02 to 1.56) and a
tilting disc versus bileaflet prosthesis for the mechanical
valve (HR: 1.74; 95% CI: 1.04 to 2.90). Age, previous
stroke, diabetes, and carotid lesions were identified as
independent predictors in patients with a stentless biological
AVR (56).
In the PARTNER randomized trial of AVR versus
TAVR, independent risk factors for early stroke were
assignment to TAVR (vs. AVR) and a smaller aortic valve
area (57). Predictors of late strokes (after 30 days) were:
1) history of stroke 6 to 12 months before the procedure;
2) non-TF candidate, reflecting a higher burden of athero-
sclerosis and more frequent vasculopathy; and 3) higher
New York Heart Association functional class (57). There
were no important differences in the frequency of late
strokes between TAVR and AVR patients.
Timing of Stroke After Procedures
The timing of stroke among 75 events observed post-AVR
in a single center over 5 years revealed that 72% occurred
within 24 h post-procedure, 17% between 24 and 72 h
post-procedure, and the remaining 11% occurred between
days 3 and 9 (58). In another study, of 63 strokes after AVR,
55% occurred within 24 h of surgery (52). An early time
course was also reported in patients after biological AVR, inwhich 19 of the 25 strokes (76%) recorded within 90 days
occurred in the first week, and 18 of these early events (95%)
were intraoperative (59). Among randomized AVR cases in
the PARTNER trial, 62.5% of the major strokes (5 of 8)
seen at 1 year occurred within the first 2 days, 25% (2 of 8)
between 5 and 30 days, and 1 (12.5%) later than 30 days
(57).
After TAVR, there appears to be a more significant
proportion of early strokes occurring 24 h post-procedure
(24,43), but TAVR patients with multiple comorbidities
are probably at higher risk of both early and late strokes. In
the inoperable patients of the PARTNER trial, 12 strokes
were reported at 30 days in the TAVR group; 1 event
occurred before the procedure (1). Of the 11 other events, 3
(27%) were observed within 24 h, 6 (55%) between days 1
and 5, and 2 (18%) after the first week. In the high-risk
patients of the PARTNER trial who received a transcath-
eter valve, 12 major strokes occurred in the first 30 days; 7
(58%) were diagnosed in the first 2 days, 9 (75%) in the first
5 days, and 3 (25%) between 5 and 30 days (57). These
observations parallel the Canadian experience in which only
25% of 30-day strokes were seen within 24 h of the
procedure (22). In high-risk and inoperable patients of the
PARTNER trial, late strokes (after 30 days) were seen in
2.8% and 3.9% of patients between 30 days and 1 year after
TAVR, respectively, representing one third of the total
stroke events at 1 year (1,2). It is still unclear whether
these late (30 days) stroke events are related to the
procedure, the antiplatelet/anticoagulation regimen, or
other comorbidities.
Outcomes After Stroke
The mortality associated with strokes after AVR is signifi-
cant. A large AVR study revealed that in-hospital mortality
for patients without stroke was 4.6% (127 of 2,754) com-
pared with 31% (11 of 35) for those with an early (24 h)
stroke and 14% (4 of 28) for those with a late (24 h) stroke
(52). A multivariable analysis from another study indicated
that post-operative stroke with permanent disability was a
strong predictor of 30-day mortality after AVR in octoge-
narian patients (OR: 11.3; 95% CI: 1.7 to 75.1) (16). Other
variables strongly associated with mortality were post-
operative renal failure (OR: 20.9; 95% CI: 6.5 to 67.6),
immunocompromised state (OR: 14; 95% CI: 1.7 to 112.3)
and intra- or post-operative intra-aortic balloon pump
requirement (OR: 14.9; 95% CI: 2.9 to 75.8).
The outcome of stroke after TAVR seems to be influenced
by the severity of the neurologic event. In patients with stroke
and no permanent deficit, data available suggest that mortality
may not be affected (24). However, inoperable patients with
major stroke post-TAVR in the PARTNER trial had signif-
icantly increased 1-year mortality rate (66.7% vs. 27.7%;
p  0.0001) compared with patients without a major
neurologic event (60).
2148 Daneault et al. JACC Vol. 58, No. 21, 2011
Stroke Associated With Aortic Stenosis Treatment November 15, 2011:2143–50Discussion
Most of the surgical AVR studies are observational and lack
prospectively assessed and adjudicated outcomes using stan-
dardized definitions for stroke. Therefore, the available
literature on stroke related to surgical AVR is inconsistent
and nondefinitive. Small prospective trials using DW-MRI
have reported a much greater rate of perfusion abnormalities
than clinical events; at present, the relevance of these
findings is unclear and the subject of further investigation.
Established risk factors for stroke after AVR include age
and left ventricular dysfunction. Further data are needed to
determine the incremental risks conferred by aortic calcifi-
cation and atrial fibrillation.
TAVR is currently restricted to high-risk patients, and
the rates of stroke after TAVR appear higher than after
AVR. In a randomized trial comparing TAVR and AVR in
high-risk patients, the AVR group had a 2-fold lower event
rate for all neurologic events and major stroke at 30 days and
1 year (2). Importantly, the data thus far generated involved
the use of early-generation high-profile TAVR devices and
operators with limited case experience, which may have
negatively influenced some of the periprocedure stroke
results. Similar to the neuroimaging data with AVR, DW-
MRI studies have demonstrated significant numbers of
imaging deficits post-TAVR, but there are limited data
associating these with significant clinical events.
In the setting of AVR or TAVR, the presence of a major
stroke is undoubtedly associated with a poor overall prog-
nosis, and efforts to reduce the rate of stroke after these
procedures are ongoing. Because a significant percentage of
these strokes appear to be procedure-related and embolic in
nature, some have suggested that active protection of the
cerebral circulation from embolic debris might be helpful. A
small feasibility (n  3) study suggested that a deflector
device covering the right brachiocephalic trunk and the left
carotid arteries may decrease neuroimaging defects post-
TAVR (61). No benefit of an intra-aortic filter had been
seen on neuroimaging outcomes in patients after cardiac
surgery (62). However, the lack of benefit may be due to
inclusion of very low risk patients in this study. The
presence of atrial fibrillation in this elderly population, often
not anticoagulated because of bleeding concerns, may be an
additional significant factor influencing the occurrence of
stroke. The role of optimal anticoagulation in these patients
is another area of active investigation.
Further prospective studies with large numbers of pa-
tients undergoing TAVR and AVR with detailed neurology
assessments, neurocognitive testing, and neuroimaging eval-
uations will need to be done to better determine the
neurologic risks of these procedures. The PARTNER 2 and
SURTAVI (SURgery and Transcatheter Aortic Valve Im-
plantation) trials, including intermediate-risk patients, will
address these issues in different substudies. As suggested by
“Current Thinking Regarding Neurological Assessments
for Transcatheter Valve Trials” by the U.S. Food and DrugAdministration (FDA communication, May 25, 2011),
neurologic and neurocognitive evaluations will be made by
neurologists to improve the quality of clinical assessments.
Conclusions
Clinical stroke after TAVR or AVR is an important
complication and is associated with a poor clinical progno-
sis. Recent randomized data showed that stroke rates appear
to be higher with TAVR compared with AVR, but with
wide CIs due the relatively low event rates. The prevalence
of delayed or late strokes after the procedure is not insig-
nificant and should generate active investigation of both
devices and adjunctive pharmacotherapy to reduce the
frequency and severity of strokes after AVR and TAVR in
the future.
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